Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Design, Synthesis, Docking Studies and Biological Activities Novel 2,3- Diaryl-4-Quinazolinone Derivatives as Anti-HIV-1 Agents.

Hajimahdi Z, Zabihollahi R, Aghasadeghi MR, Zarghi A.

Curr HIV Res. 2019;17(3):214-222. doi: 10.2174/1570162X17666190911125359.

PMID:
31518225
2.

Novel benzoxazin-3-one derivatives: Design, synthesis, molecular modeling, anti-HIV-1 and integrase inhibitory assay.

Safakish M, Hajimahdi Z, Vahabpour R, Zabihollahi R, Zarghi A.

Med Chem. 2019 Aug 26. doi: 10.2174/1573406415666190826161123. [Epub ahead of print]

PMID:
31448713
3.

Design, synthesis and biological evaluation of peptide-NSAID conjugates for targeted cancer therapy.

Shokri B, Zarghi A, Shahhoseini S, Mohammadi R, Kobarfard F.

Arch Pharm (Weinheim). 2019 Aug;352(8):e1800379. doi: 10.1002/ardp.201800379. Epub 2019 Jul 18.

PMID:
31318093
4.

Selective COX-2 inhibitors as anticancer agents: a patent review (2014-2018).

Mahboubi Rabbani SMI, Zarghi A.

Expert Opin Ther Pat. 2019 Jun;29(6):407-427. doi: 10.1080/13543776.2019.1623880. Epub 2019 May 27. Review.

PMID:
31132889
5.
6.

A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients.

Hafizi M, Kalanaky S, Moaiery H, Khayamzadeh M, Noorian S, Kaveh V, Gharib B, Foudazi H, Razavi M, Jenabian A, Salimi S, Sereshki MMA, Mirzaei HR, Zarghi A, Fakharzadeh S, Nazaran MH, Akbari ME.

J Nanobiotechnology. 2019 Apr 10;17(1):52. doi: 10.1186/s12951-019-0484-0.

7.

PAMAM-dendrimer Enhanced Antibacterial Effect of Vancomycin Hydrochloride Against Gram-Negative Bacteria.

Serri A, Mahboubi A, Zarghi A, Moghimi HR.

J Pharm Pharm Sci. 2018;22(1):10-21. doi: 10.18433/jpps29659.

8.

Novel Colchicine Analogues Target Mitochondrial PT Pores Using Free Tubulins and Induce ROS-Mediated Apoptosis in Cancerous Lymphocytes.

Aghvami M, Eshghi P, Zarei MH, Arefi H, Sattari F, Zarghi A, Pourahmad J.

Iran J Pharm Res. 2018 Fall;17(4):1476-1487.

9.

Design, Synthesis and Biological Evaluation of Ketoprofen Conjugated To RGD/NGR for Targeted Cancer Therapy.

Shokri B, Zarghi A, Shahhoseini S, Mohammadi R, Kobarfard F.

Iran J Pharm Res. 2018 Fall;17(4):1297-1305.

10.

Design, Synthesis and Biological Evaluation of New Imidazo[2,1-b]Thiazole Derivatives as Selective COX-2 Inhibitors.

Shahrasbi M, Azami Movahed M, Ghorban Dadras O, Daraei B, Zarghi A.

Iran J Pharm Res. 2018 Fall;17(4):1288-1296.

11.

Design, synthesis, and biological evaluation of new pyrazino[1,2-a]benzimidazole derivatives as selective cyclooxygenase (COX-2) inhibitors.

Azami Movahed M, Daraei B, Shahosseini S, Esfahanizadeh M, Zarghi A.

Arch Pharm (Weinheim). 2019 Feb;352(2):e1800265. doi: 10.1002/ardp.201800265. Epub 2018 Dec 18.

PMID:
30561073
12.

Targeting the mitochondrial apoptosis pathway by a newly synthesized COX-2 inhibitor in pediatric ALL lymphocytes.

Aghvami M, Salimi A, Eshghi P, Zarei MH, Farzaneh S, Sattari F, Zarghi A, Pourahmad J.

Future Med Chem. 2018 Oct 1;10(19):2277-2289. doi: 10.4155/fmc-2018-0032. Epub 2018 Oct 11.

PMID:
30304948
13.

Evaluation of Cytotoxicity Effects of Chalcone Epoxide Analogues as a Selective COX-II Inhibitor in the Human Liver Carcinoma Cell Line.

Makhdoumi P, Zarghi A, Daraei B, Karimi G.

J Pharmacopuncture. 2017 Sep;20(3):207-212. doi: 10.3831/KPI.2017.20.024. Epub 2017 Sep 30.

14.

Docking-based 3D-QSAR (CoMFA, CoMFA-RG, CoMSIA) study on hydroquinoline and thiazinan-4-one derivatives as selective COX-2 inhibitors.

Dowlati Beirami A, Hajimahdi Z, Zarghi A.

J Biomol Struct Dyn. 2019 Jul;37(11):2999-3006. doi: 10.1080/07391102.2018.1502687. Epub 2018 Nov 17.

PMID:
30035675
16.

Design, Synthesis and Biological Evaluation of New 1,3-diphenyl-3- (phenylamino)propan-1-ones as Selective Cyclooxygenase (COX-2) Inhibitors.

Farzaneh S, Shahhosseini S, Arefi H, Daraei B, Esfahanizadeh M, Zarghi A.

Med Chem. 2018;14(7):652-659. doi: 10.2174/1573406414666180525133221.

PMID:
29804536
17.

Evaluation of Ion-pair Formation of Adefovir to Improve Permeation across Artificial and Biological Membranes.

Darsazan B, Shafaati A, Zarghi A, Mortazavi SA.

J Pharm Pharm Sci. 2018;21(1):160-170. doi: 10.18433/jpps29394. Review.

18.
19.

Design, Synthesis and Biological Evaluation of Novel Peptide-Like Analogues as Selective COX-2 Inhibitors.

Ahmaditaba MA, Houshdar Tehrani MH, Zarghi A, Shahosseini S, Daraei B.

Iran J Pharm Res. 2018 Winter;17(1):87-92.

20.

STABILITY-INDICATING HPLC METHOD FOR DETERMINATION OF VANCOMYCIN HYDROCHLORIDE IN THE PHARMACEUTICAL DOSAGE FORMS.

Serri A, Moghimp HR, Mahboubi A, Zarghi A.

Acta Pol Pharm. 2017 Jan;74(1):73-79.

21.

Pharmacokinetics and Biodistribution of Pegylated Methotrexate after IV Administration to Mice.

Yousefi G, Shafaati A, Zarghi A, Foroutan SM.

Iran J Pharm Res. 2018;17(Suppl2):111-123.

22.

Design, Synthesis, Molecular Modeling, In Silico ADME Studies and Anti-HIV-1 Assay of New Diazocoumarin Derivatives.

Alimi Livani Z, Safakish M, Hajimahdi Z, Soleymani S, Zabihollahi R, Aghasadeghi MR, Alipour E, Zarghi A.

Iran J Pharm Res. 2018;17(Suppl2):65-77.

23.

A Newly Synthetized Ferrocenyl Derivative Selectively Induces Apoptosis in ALL Lymphocytes through Mitochondrial Estrogen Receptors.

Aghvami M, Pourahmad J, Zarghi A, Eshghi P, Zarei MH, Farzaneh S, Sattari F.

Anticancer Agents Med Chem. 2018;18(7):1032-1043. doi: 10.2174/1871520618666171206112446.

PMID:
29210666
24.
25.
26.

New Ferrocene Compounds as Selective Cyclooxygenase (COX-2) Inhibitors: Design, Synthesis, Cytotoxicity and Enzyme-inhibitory Activity.

Farzaneh S, Zeinalzadeh E, Daraei B, Shahhosseini S, Zarghi A.

Anticancer Agents Med Chem. 2018;18(2):295-301. doi: 10.2174/1871520617666171003145533.

PMID:
28971779
27.

Design, Synthesis, and Biological Evaluation of New Peptide Analogues as Selective COX-2 Inhibitors.

Ahmaditaba MA, Shahosseini S, Daraei B, Zarghi A, Houshdar Tehrani MH.

Arch Pharm (Weinheim). 2017 Oct;350(10). doi: 10.1002/ardp.201700158. Epub 2017 Sep 5.

PMID:
28872704
28.

An investigation into the ability of alendronate ion pairs to increase oral absorption.

Samiei N, Foroutan SM, Razipour F, Zarghi A, Shafaati A.

Int J Pharm. 2017 Jul 15;527(1-2):184-190. doi: 10.1016/j.ijpharm.2017.05.042. Epub 2017 May 25.

PMID:
28552769
29.
30.

β-lactam Structured, 4-(4-(Methylsulfonyl)phenyl)-1-pentyl-3-phenoxyazetidin-2-one: Selectively Targets Cancerous B Lymphocyte Mitochondria.

Pirahmadi N, Zarghi A, Salimi A, Arefi H, Pourahmad J.

Anticancer Agents Med Chem. 2017;17(9):1292-1301. doi: 10.2174/1871520617666170213144113.

PMID:
28270082
31.

Design and Synthesis of Pyrrolo[2,1-a]Isoquinoline-Based Derivatives as New Cytotoxic Agents.

Kakhki S, Shahosseini S, Zarghi A.

Iran J Pharm Res. 2016 Fall;15(4):743-751.

32.

Progress in HIV-1 Integrase Inhibitors: A Review of their Chemical Structure Diversity.

Hajimahdi Z, Zarghi A.

Iran J Pharm Res. 2016 Fall;15(4):595-628. Review.

33.

Estrogen Receptor Ligands: A Review (2013-2015).

Farzaneh S, Zarghi A.

Sci Pharm. 2016 Apr 13;84(3):409-427. doi: 10.3390/scipharm84030409. Review.

34.

Design, synthesis and biological evaluation of 7-(aryl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline derivatives as potential Hsp90 inhibitors and anticancer agents.

Malayeri SO, Abnous K, Arab A, Akaberi M, Mehri S, Zarghi A, Ghodsi R.

Bioorg Med Chem. 2017 Feb 1;25(3):1294-1302. doi: 10.1016/j.bmc.2016.12.050. Epub 2017 Jan 2.

PMID:
28073608
35.

QSAR Analysis for Some 1, 2-Benzisothiazol-3-one Derivatives as Caspase-3 Inhibitors by Stepwise MLR Method.

Hajimahdi Z, Safizadeh F, Zarghi A.

Iran J Pharm Res. 2016 Spring;15(2):439-48.

37.

Synthesis and biological evaluation of quinoline analogues of flavones as potential anticancer agents and tubulin polymerization inhibitors.

Shobeiri N, Rashedi M, Mosaffa F, Zarghi A, Ghandadi M, Ghasemi A, Ghodsi R.

Eur J Med Chem. 2016 May 23;114:14-23. doi: 10.1016/j.ejmech.2016.02.069. Epub 2016 Mar 2.

PMID:
26974371
38.

Design, Synthesis, and Biological Evaluation of New 2-Phenyl-4H-chromen-4-one Derivatives as Selective Cyclooxygenase-2 Inhibitors.

Zarghi A, Kakhki S.

Sci Pharm. 2014 Sep 15;83(1):15-26. doi: 10.3797/scipharm.1407-20. Print 2015 Jan-Mar.

39.

Design, Synthesis and Biological Evaluation of New 1, 4-Dihydropyridine (DHP) Derivatives as Selective Cyclooxygenase-2 Inhibitors.

Sabakhi I, Topuzyan V, Hajimahdi Z, Daraei B, Arefi H, Zarghi A.

Iran J Pharm Res. 2015 Fall;14(4):1087-93.

41.
42.
43.

In-silico Investigation of Tubulin Binding Modes of a Series of Novel Antiproliferative Spiroisoxazoline Compounds Using Docking Studies.

Abolhasani H, Zarghi A, Hamzeh-Mivehroud M, Alizadeh AA, Shahbazi Mojarrad J, Dastmalchi S.

Iran J Pharm Res. 2015 Winter;14(1):141-7.

44.

Design, Synthesis and Cytotoxicity Evaluationof New 1,2-diaryl-4, 5, 6, 7-Tetrahydro-1H-benzo[d] Imidazolesas Tubulin Inhibitors.

Amirmostofian M, Kobarfard F, Reihanfard H, Mashayekhi V, Zarghi A.

Iran J Pharm Res. 2015 Winter;14(1):59-65.

45.

Cytotoxicity of selected novel chalcone derivatives on human breast, lung and hepatic carcinoma cell lines.

Nakhjavani M, Zarghi A, H Shirazi F.

Iran J Pharm Res. 2014 Summer;13(3):953-8.

46.

Occurrence of deoxynivalenol in foods for human consumption from tehran, iran.

Yazdanpanah H, Shafaati A, Foroutan SM, Zarghi A, Aboul-Fathi F, Khoddam A, Shaki F, Nazari F.

Iran J Pharm Res. 2014 Winter;13(Suppl):87-92.

47.
48.

Design, synthesis and biological evaluation of 5-oxo-1,4,5,6,7,8 hexahydroquinoline derivatives as selective cyclooxygenase-2 inhibitors.

Zarghi A, Sabakhi I, Topuzyan V, Hajimahdi Z, Daraie B.

Iran J Pharm Res. 2014 Winter;13(Suppl):61-9.

49.

Synthesis, docking simulation, biological evaluations and 3D-QSAR study of 5-Aryl-6-(4-methylsulfonyl)-3-(metylthio)-1,2,4-triazine as selective cyclooxygenase-2 inhibitors.

Irannejad H, Kebriaieezadeh A, Zarghi A, Montazer-Sadegh F, Shafiee A, Assadieskandar A, Amini M.

Bioorg Med Chem. 2014 Jan 15;22(2):865-73. doi: 10.1016/j.bmc.2013.12.002. Epub 2013 Dec 11.

PMID:
24361187
50.

Evaluation of Anti-nociceptive and Anti-inflammatory Activities of Novel Chalcone Derivatives.

Razmi A, Zarghi A, Arfaee S, Naderi N, Faizi M.

Iran J Pharm Res. 2013 Winter;12(Suppl):153-9.

Supplemental Content

Loading ...
Support Center